Silexion Therapeutics announces attendance at the RNAi-Based Therapeutics Summit, showcasing their siRNA therapy SIL204 for cancer treatment.
Quiver AI Summary
Silexion Therapeutics Corp., a clinical-stage biotechnology company focused on oncology, has announced its participation in the 7th RNAi-Based Therapeutics Summit in Boston from January 27-29, 2026. The summit will feature discussions on RNA-based therapeutics for various diseases, and Silexion plans to present its next-generation siRNA therapy, SIL204, aimed at silencing mutated KRAS oncogenes in cancers. The company is gearing up to start a Phase 2/3 clinical study for SIL204 in locally advanced pancreatic cancer in mid-2026. Management, including CEO Ilan Hadar, will host one-on-one meetings during the event for interested parties. Silexion is an official partner of the summit and is dedicated to advancing treatment options for solid tumor cancers linked to the KRAS oncogene.
Potential Positives
- Silexion management, including CEO Ilan Hadar, will be attending the prestigious 7th RNAi-Based Therapeutics Summit, providing opportunities for visibility and networking within the industry.
- Silexion is developing SIL204, a next-generation siRNA therapy targeting KRAS oncogenes, highlighting the company's commitment to innovation in oncology.
- The planned Phase 2/3 clinical study program for SIL204 in mid 2026 indicates progress in their drug development pipeline, potentially positioning the company for future advancements in treatment for pancreatic cancer.
- As an official partner of the RNAi-Based Therapeutics Summit for 2026, Silexion strengthens its presence and credibility within the biotech community.
Potential Negatives
- The press release does not provide specific details on the timeline or expected outcomes for the upcoming Phase 2/3 clinical study, which may leave investors uncertain about the future of the product.
- While the previous Phase 2a clinical trial showed a positive trend, the lack of strong clinical data or statistical significance in the results may raise concerns about the efficacy of SIL204.
- Being in a clinical stage and not yet having a market-approved product may pose risks to investors looking for immediate returns or stability in the company's growth.
FAQ
What is the focus of Silexion Therapeutics Corp?
Silexion Therapeutics Corp. is focused on developing innovative treatments for solid tumor cancers, particularly those with mutated KRAS oncogenes.
When will Silexion present at the RNAi-Based Therapeutics Summit?
Silexion management, including CEO Ilan Hadar, will attend the summit from January 27-29, 2026, in Boston, MA.
What is SIL204 and its significance?
SIL204 is a next-generation siRNA therapy designed to silence mutated KRAS oncogenes, crucial for treating pancreatic cancer.
How can interested parties arrange meetings with Silexion at the summit?
Interested parties can contact Silexion’s Investor Relations representatives to arrange one-on-one meetings during the summit.
What are Silexion's future clinical study plans?
Silexion plans to enter a Phase 2/3 clinical study program for SIL204 in locally advanced pancreatic cancer in mid 2026.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SLXN Hedge Fund Activity
We have seen 1 institutional investors add shares of $SLXN stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WILDCAT CAPITAL MANAGEMENT, LLC removed 113,428 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $385,655
- UBS GROUP AG removed 108,565 shares (-99.4%) from their portfolio in Q3 2025, for an estimated $369,121
- MEYER HANDELMAN CO removed 32,967 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $112,087
- SBI SECURITIES CO., LTD. removed 15,354 shares (-93.5%) from their portfolio in Q3 2025, for an estimated $52,203
- VIRTU FINANCIAL LLC removed 14,264 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $48,497
- STONEX GROUP INC. removed 11,241 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $38,219
- MONTAG A & ASSOCIATES INC added 3,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $10,200
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management, including CEO Ilan Hadar, will attend the 7th RNAi-Based Therapeutics Summit, taking place January 27-29 in Boston, MA.
The 7th RNAi-Based Therapeutics Summit is the industry's premier forum inviting drug developers to discuss RNA-based therapeutics for neurological, metabolic, cardiovascular, and oncological diseases. Silexion is developing SIL204, a next-generation siRNA therapy designed to silence mutated KRAS oncogenes - the most common oncogenic driver in human cancers. SIL204 is planned to enter a Phase 2/3 clinical study program in locally advanced pancreatic cancer in mid 2026.
Silexion management will host one-on-one meetings during the summit. Interested parties should contact the Company’s Investor Relations representatives who can arrange such meetings.
Silexion is pleased to be an official partner of the RNAi-Based Therapeutics Summit
for 2026.
About Silexion Therapuetics
Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer. For more information please visit:
https://silexion.com
Company Contact:
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
[email protected]
Investor Relations
Arx Investor Relations
North American Equities Desk
[email protected]
